跳至正文

Knockgene Biotech

Possible indications

The ability to actively recruit immune cells gives KN330 wider indication. We don’t have to worry about whether this is a hot tumor or a cold tumor. In either case, KN330 can allow immune cells to infiltrate into the tumor, and the latter will play an anti-tumor role. Therefore, we can speculate that KN330 is applicable to malignant tumors in all parts of body including the liver, lung, breast, skin, nervous system, as well as malignant tumors of all cell sources such as soft tissue cells, squamous cells, glandular cells, hepatocytes, epithelial cells, mast cells, lymphocytes, etc. In hundreds of mouse models of various types and hundreds of real-world dog / cat cases, the indication range of KN330 is consistent with our speculation.

About us

The team

 Knockgene was founded by several highly creative scientists from China. The main office locates in Beijing. The team believes that de novo designed drug can treat diseases better. With our unique insights into the immune system and the innovative drug screening platform, we have made some interesting discoveries in the field of immune related diseases. We look forward to finding more drugs with excellent efficacy and reliable safety.

Our mission

The team is committed to developing the first in class immunotherapeutic drugs. The company is established to the development and improvement of the drugs in the companion animal market.

Investment & Cooperation

If you want to invest, patent licensing, joint development cooperation, welcome!